Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. The company is headquartered in Osaka, Osaka-Fu and currently employs 4,955 full-time employees. The firm is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The firm is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The firm provides products and services in Japan, Europe, North America, and other regions.
Shionogi & Co Ltd 주요 수익원은 Pharmaceutical이며, 최신 수익 발표에서 수익은 438,268,000,000입니다. 지역별로는 United Kingdom이 Shionogi & Co Ltd의 주요 시장이며, 수익은 245,512,000,000입니다.
Shionogi & Co Ltd은 수익성이 있나요?
예, 최신 재무제표에 따르면 Shionogi & Co Ltd의 순이익은 $170,435입니다.